Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
LNCR3
MCID: LNG064
MIFTS: 71

Lung Cancer Susceptibility 3 (LNCR3)

Categories: Cancer diseases, Rare diseases, Respiratory diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Lung Cancer Susceptibility 3

About this section

MalaCards integrated aliases for Lung Cancer Susceptibility 3:

Name: Lung Cancer Susceptibility 3 57 12 71 75
Lung Adenocarcinoma 11 19 28 5 14 16
Adenocarcinoma of Lung 57 11 75 43 71
Adenocarcinoma of Lung, Susceptibility to 57
Bronchogenic Lung Adenocarcinoma 11
Non-Small Cell Adenocarcinoma 71
Nonsmall Cell Adenocarcinoma 11
Lung Adenocarcinomas 14
Adenocarcinoma Lung 53
Lncr3 57

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Respiratory diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 11 DOID:3910
OMIM® 57 612571
MeSH 43 D000077192
NCIt 49 C27745 C3512
SNOMED-CT 68 254626006
UMLS 71 C0152013 C1335060 C2675497
Sources

Summaries for Lung Cancer Susceptibility 3

About this section

GARD: 19 Lung adenocarcinoma is a cancer that occurs due to abnormal and uncontrolled cell growth in the lungs. It is a subtype of non-small cell lung cancer that is often diagnosed in an outer area of the lung. Early lung cancers may not be associated with any signs and symptoms. As the condition progresses, affected people can experience chest pain, a persistent cough, fatigue, coughing up blood, loss of appetite, unexplained weight loss, shortness of breath, and/or wheezing.

MalaCards based summary: Lung Cancer Susceptibility 3, also known as lung adenocarcinoma, is related to lung cancer and mucinous lung adenocarcinoma. An important gene associated with Lung Cancer Susceptibility 3 is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are mTOR Signaling and 22q11.2 copy number variation syndrome. The drugs Endostatins and Endostar protein have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and brain.

Disease Ontology: 11 A lung non-small cell carcinoma that derives from epithelial cells of glandular origin.

Wikipedia 75 Lung cancer susceptibility 3: Lung cancer susceptibility 3 is a protein that in humans is encoded by the LNCR3... more...

Adenocarcinoma of lung: Adenocarcinoma of the lung is the most common type of lung cancer, and like other forms of lung cancer,... more...

More information from OMIM: 612571
Sources

Related Diseases for Lung Cancer Susceptibility 3

About this section

Diseases in the Lung Cancer Susceptibility 3 family:

Lung Cancer Susceptibility 1 Lung Cancer Susceptibility 4
Lung Cancer Susceptibility 5

Diseases related to Lung Cancer Susceptibility 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1017)
# Related Disease Score Top Affiliating Genes
1 lung cancer 34.0 TUG1 ROS1 PRKN MALAT1 LINC-ROR KCNQ1OT1
2 mucinous lung adenocarcinoma 33.1 ROS1 EGFR
3 high grade glioma 32.8 TUG1 MALAT1 LINC-ROR HOTAIR GAS5 EGFR
4 small cell cancer of the lung 32.4 TUG1 MALAT1 HOTAIR EGFR
5 lung squamous cell carcinoma 32.3 TUG1 EGFR CCAT1 BRAF
6 hepatocellular carcinoma 32.2 TUG1 PRKN MALAT1 LINC00941 LINC-ROR KCNQ1OT1
7 adenocarcinoma 32.1 ROS1 MALAT1 ERBB2 EGFR BRAF
8 renal cell carcinoma, nonpapillary 32.0 TUG1 MALAT1 LINC-ROR KCNQ1OT1 HOTAIR GAS5
9 gastric cancer 31.9 TUG1 MALAT1 LINC00941 LINC-ROR KCNQ1OT1 HOTAIR
10 thyroid carcinoma 31.7 MALAT1 HOTAIR GAS5 BRAF AFAP1-AS1
11 glioblastoma 31.7 TUG1 ROS1 MALAT1 HOTAIR GAS5 ERBB2
12 retinitis pigmentosa 11 31.7 TUG1 HOTAIR GAS5 EGFR DGCR5 CYTOR
13 bladder cancer 31.6 TUG1 MALAT1 HOTAIR GAS5 ERBB2 EGFR
14 esophageal cancer 31.5 MIR375 MALAT1 KCNQ1OT1 HOTAIR GAS5 ERBB2
15 thyroid cancer, nonmedullary, 1 31.5 MALAT1 LINC-ROR HOTAIR BRAF
16 kidney cancer 31.5 MALAT1 KCNQ1OT1 HOTAIR GAS5 EGFR
17 large cell carcinoma 31.5 ROS1 ERBB2 EGFR
18 neuroblastoma 31.4 PRKN MALAT1 HOTAIR GAS5 ERBB2 EGFR
19 osteogenic sarcoma 31.4 TUG1 MALAT1 HOTAIR GAS5 FENDRR CCAT1
20 squamous cell carcinoma 31.4 TUG1 MALAT1 HOTAIR ERBB2 EGFR BRAF
21 cholangiocarcinoma 31.4 TUG1 ROS1 MALAT1 ERBB2 EGFR BRAF
22 nasopharyngeal carcinoma 31.4 MALAT1 LINC-ROR HOTAIR GAS5 EGFR CCAT1
23 esophagus squamous cell carcinoma 31.3 TUG1 MALAT1 LINC-ROR HOTAIR GAS5 EGFR
24 endometrial cancer 31.3 TUG1 LINC-ROR HOTAIR GAS5 ERBB2 EGFR
25 glioma 31.3 MALAT1 HOTAIR GAS5 EGFR CYTOR CCAT1
26 cervical cancer 31.3 TUG1 MALAT1 HOTAIR GAS5 ERBB2 CCAT1
27 colorectal cancer 31.3 TUG1 ROS1 MALAT1 LINC00472 LINC-ROR KCNQ1OT1
28 pancreatic cancer 31.2 TUG1 MIR375 MALAT1 LINC-ROR HOTAIR GAS5
29 breast cancer 31.2 TUG1 MALAT1 LINC00472 LINC-ROR KCNQ1OT1 HOTAIR
30 ovarian cancer 31.2 TUG1 PRKN MALAT1 LINC00472 LINC-ROR HOTAIR
31 squamous cell carcinoma, head and neck 31.2 MIR375 HOTAIR ERBB2 EGFR CYTOR BRAF
32 oral squamous cell carcinoma 31.1 TUG1 MALAT1 HOTAIR CCAT1
33 melanoma, uveal 31.1 MALAT1 ERBB2 EGFR BRAF
34 paronychia 31.0 ERBB2 EGFR
35 colonic benign neoplasm 31.0 ERBB2 EGFR BRAF
36 mantle cell lymphoma 31.0 MALAT1 GAS5 ERBB2 EGFR
37 leukemia, acute myeloid 31.0 TUG1 MALAT1 HOTAIR ERBB2 EGFR CCAT1
38 wilms tumor 1 30.9 KCNQ1OT1 ERBB2 EGFR BRAF
39 esophagus adenocarcinoma 30.9 ERBB2 EGFR AFAP1-AS1
40 mucinous adenocarcinoma 30.9 ROS1 ERBB2 EGFR
41 pancreatic ductal adenocarcinoma 30.8 MIR375 MALAT1 HOTAIR AFAP1-AS1
42 gastrointestinal stromal tumor 30.8 ROS1 HOTAIR ERBB2 EGFR BRAF
43 lung sarcomatoid carcinoma 30.8 ROS1 EGFR
44 bladder urothelial carcinoma 30.8 TUG1 MALAT1 HOTAIR GAS5 ERBB2 BRAF
45 brain glioma 30.8 ERBB2 EGFR DGCR5
46 suppression of tumorigenicity 12 30.8 ERBB2 EGFR BRAF
47 lymphangitis 30.7 ROS1 ERBB2 EGFR
48 skin squamous cell carcinoma 30.7 HOTAIR ERBB2 EGFR BRAF
49 intrahepatic cholangiocarcinoma 30.7 TUG1 ERBB2 EGFR CCAT1
50 glioma susceptibility 1 30.6 ERBB2 DGCR5 CYTOR

Graphical network of the top 20 diseases related to Lung Cancer Susceptibility 3:



Diseases related to Lung Cancer Susceptibility 3
Sources

Symptoms & Phenotypes for Lung Cancer Susceptibility 3

About this section

Clinical features from OMIM®:

612571 (Updated 08-Dec-2022)

Sources

Drugs & Therapeutics for Lung Cancer Susceptibility 3

About this section

Drugs for Lung Cancer Susceptibility 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Endostatins Phase 4
2 Endostar protein Phase 4
3
Vinorelbine Approved, Investigational Phase 3 71486-22-1 44424639 60780
4
Afatinib Approved Phase 3 439081-18-2, 850140-72-6 53445376 10184653
5
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
6
Ipilimumab Approved Phase 2, Phase 3 477202-00-9
7
Cetuximab Approved Phase 3 205923-56-4
8
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
9
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
10
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 60843 446556 135565230
11
Erlotinib Approved, Investigational Phase 3 183319-69-9, 183321-74-6 176870
12
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
13
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
14
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
15
Xylometazoline Approved, Investigational Phase 3 526-36-3 5709
16
Mecobalamin Approved, Investigational Phase 3 13422-55-4
17
Hydroxocobalamin Approved Phase 3 13422-51-0 15589840 44475014
18
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
19
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 3 133585-56-5, 60-18-4, 556-02-5 1153 6057
20
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 24892734 16212801 44176380
21
Cobalamin Experimental Phase 3 13408-78-1 6857388
22 Antibodies, Monoclonal Phase 2, Phase 3
23 Immunoglobulins, Intravenous Phase 2, Phase 3
24 Immunologic Factors Phase 2, Phase 3
25 Mitogens Phase 3
26 Dermatologic Agents Phase 3
27 Protective Agents Phase 3
28 Shark Cartilage Phase 3
29
2,2'-dithiodiethanesulfonic acid Phase 3 65626
30 Liver Extracts Phase 3
31 Anesthetics Phase 3
32 Immunoglobulin G Phase 3
33 Endothelial Growth Factors Phase 3
34 Folic Acid Antagonists Phase 3
35 Folate Phase 3
36 Vitamin B9 Phase 3
37 Vitamin B Complex Phase 3
38 Antineoplastic Agents, Immunological Phase 3
39 Angiogenesis Inhibitors Phase 3
40 Vitamins Phase 3
41 Vitamin B12 Phase 3
42 Vitamin B 12 Phase 3
43
Nedaplatin Approved, Investigational Phase 2 95734-82-0
44
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 2 14838-15-4, 492-39-7 131954576 4786 26934
45
Guaifenesin Approved, Investigational, Vet_approved Phase 2 93-14-1 3516
46
Trametinib Approved Phase 1, Phase 2 871700-17-3 11707110
47
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
48
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
49
Aflibercept Approved Phase 2 862111-32-8 124490314
50
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316

Interventional clinical trials:

(show top 50) (show all 257)
# Name Status NCT ID Phase Drugs
1 A Randomized ,Opened, Prospective Controlled Trial of Clinical Effectiveness for Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With Epidermal Growth Factor Receptor Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
2 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
3 Recombinant Human Endostatin Durative Transfusion Combined With Pemetrexed Plus Cisplatin or Carboplatin in the First-line Treatment of Advanced Lung Adenocarcinoma With Wild-type EGFR or ALK-negative Unknown status NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
4 Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Unknown status NCT01665417 Phase 4 Experimental;Chemotherapy
5 Comparative Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Unknown status NCT02399566 Phase 4 Erlotinib, Pemetrexed
6 Open Label Study of Erlotinib (Tarceva®) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
7 Comparison of Video-assisted Thoracoscopic Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion Unknown status NCT02011997 Phase 3
8 A Multi-center Phase III Randomized Controlled Trial Comparing Between Adjuvant Chemotherapy and Observation in High Risk Patients With Completely Resected Stage Ib Lung Adenocarcinoma Unknown status NCT02281708 Phase 3 vinorelbine plus cisplatin
9 Pemetrexed Disodium and Cisplatin Chemotherapy Combined With Synchronous Gefitinib vs Chemotherapy Alone as Adjuvent Therapy in Patient With Stage II-IIIA, Epidermal Growth Factor Receptor Mutant Expressing Lung Adenocarcinoma Unknown status NCT02518802 Phase 3 Gefitinib;Pemetrexed
10 Clinical Study of Yiqi-yangyin-jiedu Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma Patients With Activating EGFR Mutation Unknown status NCT02929693 Phase 3 gefitinib;Yiqi-yangyin-jiedu decoction;placebo
11 Conmana Versus Pemetrexed-based First-line Induction and Maintenance Chemotherapy in Advanced Lung Adenocarcinoma With EGFR-mutation Completed NCT01719536 Phase 3 Icotinib;Chemotherapy
12 Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect Completed NCT05204758 Phase 3 TCM Formula;Placebo
13 A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With Consolidation Docetaxel Followed by Maintenance Therapy With ZD1839 (NSC-715055) or Placebo in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
14 Randomized Phase II/III Trial of Paclitaxel Plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients With Advanced Nonsquamous NSCLC Completed NCT00021060 Phase 2, Phase 3 paclitaxel;carboplatin
15 Multicenter, Open-Ended, Double-Blind, Placebo-Controlled, Phase III Study of AE-941 in Addition to Combined Modality Treatment (Chemotherapy/Radiotherapy) for Locally Advanced Unresectable Non-Small Cell Lung Cancer Completed NCT00005838 Phase 3 shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
16 A PHASE III STUDY OF ADJUVANT CHEMOTHERAPY AFTER RESECTION FOR PATIENTS WITH T2N0 STAGE I NON-SMALL CELL CARCINOMA OF THE LUNG Completed NCT00002852 Phase 3 paclitaxel;carboplatin
17 A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer Completed NCT00049543 Phase 3 gefitinib
18 Randomized, Multicenter, Double-blind, Phase 3 Trial of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin Completed NCT00966914 Phase 3 Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel;Placebo in combination with cisplatin and docetaxel or paclitaxel
19 Study of Chinese Medicine Plus Targeted Therapy Maintenance Versus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma: A Randomized Double-blind Controlled Clinical Trial Completed NCT02889692 Phase 3 YiQiFang;YangYinFang;YiQiYangYinFang;placebo granules;Erlotinib®;Gefitinib®;Icotinib®
20 A Randomized Phase III Study of Gefitinib (IRESSATM) Versus Standard Chemotherapy (Gemcitabine Plus Cisplatin) as First-line Treatment for in Never Smokers Advance or Metastatic Adenocarcinoma of Lung Completed NCT00455936 Phase 3 Gefitinib
21 A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer Recruiting NCT04929041 Phase 2, Phase 3 Carboplatin;Nab-paclitaxel;Paclitaxel;Pemetrexed
22 Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in First-line Treatment for Patients With Metastatic Lung Adenocarcinoma: A Randomized Phase III Study Recruiting NCT04339218 Phase 3 Pembrolizumab;Pemetrexed;Carboplatin
23 Adjuvant Chemotherapy Versus Observation in Fully Resected Stage I Lung Adenocarcinoma With High Risk of Post-operative Recurrence Recruiting NCT03380468 Phase 2, Phase 3 cisplatin plus pemetrexed
24 Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR) Recruiting NCT03391869 Phase 3
25 A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
26 A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT03676192 Phase 3 CT-16;Avastin
27 Tyrosine-kinase Inhibitor （TKI） With or Without SBRT in Newly Diagnosed EGFRm Advanced Staged Lung Adenocarcinoma Terminated NCT02893332 Phase 3 TKI (Gefitinib or Tarceva )
28 A Randomized, Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced Non-Small-Cell Lung Adenocarcinoma Terminated NCT01798485 Phase 3 Docetaxel;Ganetespib
29 Multicentric, Randomized, Phase III Trial Comparing 2 Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Asymptomatic Brain Metastases Terminated NCT02162537 Phase 3 Cisplatin;Pemetrexed;Bevacizumab
30 Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in the Treatment of Advanced Lung Adenocarcinoma: a Single-arm, Phase Ⅱ Clinical Trial Unknown status NCT04310943 Phase 2 Tislelizumab
31 Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma Who Refused Chemotherapy: an Open, Single-arm, Single-center Clinical Trial Unknown status NCT03728374 Phase 2 Anlotinib
32 An Open-label, Randomized, Phase II Study of Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of Stage IIIA Lung Adenocarcinoma With Epidermal Growth Factor Receptor Gene Mutation. Unknown status NCT02036359 Phase 2 erlotinib;docetaxel
33 Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma Unknown status NCT02980991 Phase 2 Pemetrexed;Cisplatin
34 A Single-armed Phase Ⅱ Study of Bevacizumab Maintenance Therapy After Chemoradiotherapy for Locally Advanced Lung Adenocarcinoma Unknown status NCT03904563 Phase 2 Bevacizumab;concurrent chemotherapy
35 High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases Unknown status NCT02284490 Phase 2 pemetrexed
36 A Single-Armed Phase II Study of Radiation and Bevacizumab Maintenance Therapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene Unknown status NCT03905317 Phase 2 Bevacizumab Injection;concurrent chemotherapy
37 Chemotherapy Plus Gefitinib Versus Gefitinib Alone as First-line Treatment for Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial Unknown status NCT02951637 Phase 2 Pemetrexed plus carboplatin combined with gefitinib;Gefitinib
38 Tarceva With or Without Apatinib in the First-line Therapy of Advanced Lung Adenocarcinoma With Mutant EGFR:a Phase II Study. Unknown status NCT02704767 Phase 2 Apatinib;Tarceva;Placebo
39 A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR(Epidermal Growth Factor Receptor) Mutant Lung Adenocarcinoma Unknown status NCT02146118 Phase 2 Erlotinib
40 Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm Unknown status NCT03254004 Phase 2 Pembrolizumab
41 Effectiveness and Safety of Adding Bevacizumab to Chemotherapy in Patients With Advanced Lung Adenocarcinoma With Stable Disease After 2 Cycles of First Line Combination Chemotherapy: a Multicenter, Prospective Cohort Study Unknown status NCT03240549 Phase 2 bevacizumab
42 A Single-Arm Phase II Clinical Trial of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma Unknown status NCT03376737 Phase 2 Apatinib
43 Survival Analysis of A Chinese Randomized Crossover Study Comparing Erlotinib to Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations Unknown status NCT01131429 Phase 2 Erlotinib;Docetaxel;Cisplatin
44 The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar Unknown status NCT01564329 Phase 2 endostar
45 A Randomized Placebo-controlled Phase II Study of Intercalated Administration of Pemetrexed/Cisplatin With Iressa® (Gefitinib) or Placebo as First-line Treatment of Stage IIIB/IV Lung Adenocarcinoma in Never-smokers Unknown status NCT01502202 Phase 2 Gefitinib;Placebo;Pemetrexed plusCIsplatin
46 Crizotinib Combined With Bevacizumab as First-line Therapy in Metastatic Lung Adenocarcinoma Cancer With ALK Translocation or MET Amplification or ROS1 Translocation (CAMAR) Unknown status NCT02946359 Phase 2 Crizotinib, bevacizumab
47 A Phase II Trial of Hypofractionated Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy Unknown status NCT02787447 Phase 2 TKI;Thymosin Alpha 1
48 A Single Armed Phase ⅡStudy of Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation Unknown status NCT02737774 Phase 2 Icotinib;Pemetrexed/Carboplatin
49 A Phase II Trial of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy Unknown status NCT02788058 Phase 2 EGFR-TKI
50 An Open-label Phase II Trial of Gefitinib and Berberine in Patients With Advanced Non-small Cell Lung Cancer and Activating EGFR Mutations Unknown status NCT03486496 Phase 2 gefitinib;Berberine

Search NIH Clinical Center for Lung Cancer Susceptibility 3

Cochrane evidence based reviews: adenocarcinoma of lung

Sources

Genetic Tests for Lung Cancer Susceptibility 3

About this section

Genetic tests related to Lung Cancer Susceptibility 3:

# Genetic test Affiliating Genes
1 Lung Adenocarcinoma 28
Sources

Anatomical Context for Lung Cancer Susceptibility 3

About this section

Organs/tissues related to Lung Cancer Susceptibility 3:

MalaCards : Lung, Lymph Node, Brain, T Cells, Endothelial, Breast, Bone
Sources

Publications for Lung Cancer Susceptibility 3

About this section

Articles related to Lung Cancer Susceptibility 3:

(show top 50) (show all 23303)
# Title Authors PMID Year
1
LKB1 modulates lung cancer differentiation and metastasis. 53 62 5
17676035 2007
2
Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. 53 62 5
12719539 2003
3
Missense mutations of the BRAF gene in human lung adenocarcinoma. 53 62 5
12460919 2002
4
MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma. 62 5
25823662 2015
5
Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation. 62 5
25044103 2014
6
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. 62 5
24569458 2014
7
Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. 62 5
24327273 2014
8
Acquired resistance to crizotinib from a mutation in CD74-ROS1. 62 5
23724914 2013
9
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. 62 5
22980975 2012
10
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. 62 5
22908275 2012
11
Somatic mutations affect key pathways in lung adenocarcinoma. 62 5
18948947 2008
12
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. 62 5
15737014 2005
13
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
14
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 5
25157968 2014
15
Ceritinib in ALK-rearranged non-small-cell lung cancer. 5
24670165 2014
16
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. 5
22773810 2012
17
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. 5
22277784 2012
18
A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. 57
21725308 2011
19
Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation. 5
24212795 2011
20
Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. 5
20942962 2010
21
A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. 57
19836008 2009
22
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. 57
19151717 2009
23
Lung cancer susceptibility locus at 5p15.33. 57
18978790 2008
24
Common 5p15.33 and 6p21.33 variants influence lung cancer risk. 57
18978787 2008
25
Somatic mutations of the protein kinase gene family in human lung cancer. 5
16140923 2005
26
Lung cancer: intragenic ERBB2 kinase mutations in tumours. 5
15457249 2004
27
BRAF mutations in metastatic melanoma: a possible association with clinical outcome. 5
12960123 2003
28
KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer. 53 62
19854534 2010
29
Comparative proteome analysis of human adenocarcinoma. 53 62
19381893 2010
30
HIF-1 alpha signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells. 53 62
20347035 2010
31
Diagnosis of synchronous primary lung adenocarcinomas based on epidermal growth factor (EGFR) gene status: A case report. 53 62
20307913 2010
32
Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. 53 62
19589612 2010
33
Quantitative analysis of HGF and EGF-dependent phosphotyrosine signaling networks. 53 62
20222723 2010
34
RUNX3 modulates DNA damage-mediated phosphorylation of tumor suppressor p53 at Ser-15 and acts as a co-activator for p53. 53 62
20353948 2010
35
Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypes. 53 62
20061363 2010
36
Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. 53 62
20150826 2010
37
Secreted phosphoprotein 1 upstream invasive network construction and analysis of lung adenocarcinoma compared with human normal adjacent tissues by integrative biocomputation. 53 62
19949890 2010
38
Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. 53 62
20154720 2010
39
Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma. 53 62
20350214 2010
40
Lung adenocarcinoma cells floating in lymphatic vessels resist anoikis by expressing phosphorylated Src. 53 62
20146241 2010
41
Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis. 53 62
19540014 2010
42
Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. 53 62
20093391 2010
43
EGFR mutations and the terminal respiratory unit. 53 62
20135199 2010
44
Sex differences in estrogen receptor subcellular location and activity in lung adenocarcinoma cells. 53 62
19556604 2010
45
Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. 53 62
19130320 2010
46
Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. 53 62
20052735 2010
47
Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. 53 62
19855375 2010
48
Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. 53 62
19740516 2010
49
Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. 53 62
20007486 2010
50
Naphtho[1,2-b]furan-4,5-dione inactivates EGFR and PI3K/Akt signaling pathways in human lung adenocarcinoma A549 cells. 53 62
20036260 2010
Sources

Variations for Lung Cancer Susceptibility 3

About this section

ClinVar genetic disease variations for Lung Cancer Susceptibility 3:

5 (show top 50) (show all 398)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 EGFR NM_005228.5(EGFR):c.2492G>A (p.Arg831His) SNV Pathogenic
 560007 rs150036236 GRCh37: 7:55259434-55259434
GRCh38: 7:55191741-55191741
2 PRKN and overlap with 1 gene(s) NM_013988.2(PARK2):c.(8_8)_(171_171)+180544del DEL Pathogenic
 7049 GRCh37:
GRCh38: 6:162262766-162727661
3 ERBB2 NM_004448.4(ERBB2):c.2313_2324dup (p.Tyr772_Ala775dup) DUP Pathogenic
 13875 rs397516975 GRCh37: 17:37880981-37880982
GRCh38: 17:39724728-39724729
4 ERBB2 NM_004448.4(ERBB2):c.2328_2336dup (p.Val777_Ser779dup) DUP Pathogenic
 13876 rs587776805 GRCh37: 17:37880998-37880999
GRCh38: 17:39724745-39724746
5 ERBB2 NM_004448.4(ERBB2):c.2263_2264delinsCC (p.Leu755Pro) INDEL Pathogenic
 13877 rs121913469 GRCh37: 17:37880219-37880220
GRCh38: 17:39723966-39723967
6 BRAF NM_004333.6(BRAF):c.1790T>G (p.Leu597Arg) SNV Pathogenic
 13968 rs121913366 GRCh37: 7:140453145-140453145
GRCh38: 7:140753345-140753345
7 ERBB2 NM_004448.4(ERBB2):c.2606T>G (p.Leu869Arg) SNV Pathogenic
 431024 rs1131692237 GRCh37: 17:37881414-37881414
GRCh38: 17:39725161-39725161
8 EGFR NM_005228.5(EGFR):c.988G>A (p.Glu330Lys) SNV Pathogenic
 560008 rs139429793 GRCh37: 7:55223621-55223621
GRCh38: 7:55155928-55155928
9 BRAF NM_004333.6(BRAF):c.1397G>T (p.Gly466Val) SNV Pathogenic/Likely Pathogenic
 13967 rs121913351 GRCh37: 7:140481411-140481411
GRCh38: 7:140781611-140781611
10 ROS1 NM_001378902.1(ROS1):c.6076G>A (p.Gly2026Arg) SNV Pathogenic/Likely Pathogenic
 376139 rs1057519788 GRCh37: 6:117638347-117638347
GRCh38: 6:117317184-117317184
11 BRAF NM_004333.6(BRAF):c.1786G>C (p.Gly596Arg) SNV Likely Pathogenic
 375943 rs121913361 GRCh37: 7:140453149-140453149
GRCh38: 7:140753349-140753349
12 B2M NM_004048.4(B2M):c.2T>C (p.Met1Thr) SNV Likely Pathogenic
 376371 rs1057519879 GRCh37: 15:45003746-45003746
GRCh38: 15:44711548-44711548
13 PIK3CA NM_006218.4(PIK3CA):c.1625A>T (p.Glu542Val) SNV Likely Pathogenic
 376474 rs1057519927 GRCh37: 3:178936083-178936083
GRCh38: 3:179218295-179218295
14 DNMT3A NM_022552.5(DNMT3A):c.2645G>C (p.Arg882Pro) SNV Likely Pathogenic
 375880 rs147001633 GRCh37: 2:25457242-25457242
GRCh38: 2:25234373-25234373
15 B2M NM_004048.4(B2M):c.1A>G (p.Met1Val) SNV Likely Pathogenic
 376369 rs1023835002 GRCh37: 15:45003745-45003745
GRCh38: 15:44711547-44711547
16 HRAS, LRRC56 NM_005343.4(HRAS):c.38G>T (p.Gly13Val) SNV Likely Pathogenic
 180848 rs104894226 GRCh37: 11:534285-534285
GRCh38: 11:534285-534285
17 KRAS NM_004985.5(KRAS):c.183A>T (p.Gln61His) SNV Likely Pathogenic
 45117 rs17851045 GRCh37: 12:25380275-25380275
GRCh38: 12:25227341-25227341
18 EGFR NM_005228.5(EGFR):c.2582T>A (p.Leu861Gln) SNV Likely Pathogenic
 163380 rs121913444 GRCh37: 7:55259524-55259524
GRCh38: 7:55191831-55191831
19 PIK3CA NM_006218.4(PIK3CA):c.333G>C (p.Lys111Asn) SNV Likely Pathogenic
 376483 rs1057519934 GRCh37: 3:178916946-178916946
GRCh38: 3:179199158-179199158
20 BRAF NM_004333.6(BRAF):c.1742A>C (p.Asn581Thr) SNV Likely Pathogenic
 376376 rs121913370 GRCh37: 7:140453193-140453193
GRCh38: 7:140753393-140753393
21 ALK NM_004304.5(ALK):c.3617C>A (p.Ser1206Tyr) SNV Likely Pathogenic
 376133 rs1057519782 GRCh37: 2:29443600-29443600
GRCh38: 2:29220734-29220734
22 PIK3CA NM_006218.4(PIK3CA):c.332A>G (p.Lys111Arg) SNV Likely Pathogenic
 376484 rs1057519935 GRCh37: 3:178916945-178916945
GRCh38: 3:179199157-179199157
23 ALK NM_004304.5(ALK):c.3806G>C (p.Gly1269Ala) SNV Likely Pathogenic
 376132 rs1057519781 GRCh37: 2:29432682-29432682
GRCh38: 2:29209816-29209816
24 PPP2R1A NM_014225.6(PPP2R1A):c.548G>A (p.Arg183Gln) SNV Likely Pathogenic
 376506 rs1057519947 GRCh37: 19:52715983-52715983
GRCh38: 19:52212730-52212730
25 PIK3CA NM_006218.4(PIK3CA):c.1359A>T (p.Glu453Asp) SNV Likely Pathogenic
 376472 rs1057519926 GRCh37: 3:178928081-178928081
GRCh38: 3:179210293-179210293
26 MAP2K1 NM_002755.4(MAP2K1):c.362G>C (p.Cys121Ser) SNV Likely Pathogenic
 375980 rs1057519731 GRCh37: 15:66729154-66729154
GRCh38: 15:66436816-66436816
27 ALK NM_004304.5(ALK):c.3586C>A (p.Leu1196Met) SNV Likely Pathogenic
 376135 rs1057519784 GRCh37: 2:29443631-29443631
GRCh38: 2:29220765-29220765
28 BRAF NM_004333.6(BRAF):c.1802A>C (p.Lys601Thr) SNV Likely Pathogenic
 44818 rs397507484 GRCh37: 7:140453133-140453133
GRCh38: 7:140753333-140753333
29 RHOA NM_001664.4(RHOA):c.118G>C (p.Glu40Gln) SNV Likely Pathogenic
 376517 rs1057519951 GRCh37: 3:49412905-49412905
GRCh38: 3:49375472-49375472
30 ERBB2 NM_004448.4(ERBB2):c.929C>T (p.Ser310Phe) SNV Likely Pathogenic
 376189 rs1057519816 GRCh37: 17:37868208-37868208
GRCh38: 17:39711955-39711955
31 BRAF NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly) SNV Likely Pathogenic
 13972 rs121913338 GRCh37: 7:140453154-140453154
GRCh38: 7:140753354-140753354
32 ALK NM_004304.5(ALK):c.3522C>A (p.Phe1174Leu) SNV Likely Pathogenic
 217851 rs863225281 GRCh37: 2:29443695-29443695
GRCh38: 2:29220829-29220829
33 MYC NM_002467.6(MYC):c.173C>T (p.Pro58Leu) SNV Likely Pathogenic
 376459 rs1057519918 GRCh37: 8:128750636-128750636
GRCh38: 8:127738390-127738390
34 BRAF NM_004333.6(BRAF):c.1406G>T (p.Gly469Val) SNV Likely Pathogenic
 44803 rs121913355 GRCh37: 7:140481402-140481402
GRCh38: 7:140781602-140781602
35 CDKN2A NM_000077.5(CDKN2A):c.247C>G (p.His83Asp) SNV Likely Pathogenic
 376380 rs121913385 GRCh37: 9:21971111-21971111
GRCh38: 9:21971112-21971112
36 CTNNB1 NM_001904.4(CTNNB1):c.134C>G (p.Ser45Cys) SNV Likely Pathogenic
 376242 rs121913409 GRCh37: 3:41266137-41266137
GRCh38: 3:41224646-41224646
37 ARAF NM_001654.5(ARAF):c.640T>G (p.Ser214Ala) SNV Likely Pathogenic
 376367 rs1057519876 GRCh37: X:47426120-47426120
GRCh38: X:47566721-47566721
38 MAP2K1 NM_002755.4(MAP2K1):c.157T>G (p.Phe53Val) SNV Likely Pathogenic
 376446 rs1057519728 GRCh37: 15:66727441-66727441
GRCh38: 15:66435103-66435103
39 ARAF NM_001654.5(ARAF):c.641C>T (p.Ser214Phe) SNV Likely Pathogenic
 376366 rs1057519786 GRCh37: X:47426121-47426121
GRCh38: X:47566722-47566722
40 U2AF1 NM_006758.3(U2AF1):c.101C>T (p.Ser34Phe) SNV Likely Pathogenic
 376025 rs371769427 GRCh37: 21:44524456-44524456
GRCh38: 21:43104346-43104346
41 NFE2L2 NM_006164.5(NFE2L2):c.85G>A (p.Asp29Asn) SNV Likely Pathogenic
 376463 rs1057519920 GRCh37: 2:178098960-178098960
GRCh38: 2:177234232-177234232
42 BRAF NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala) SNV Likely Pathogenic
 13971 rs121913355 GRCh37: 7:140481402-140481402
GRCh38: 7:140781602-140781602
43 MYC NM_002467.6(MYC):c.218C>T (p.Thr73Ile) SNV Likely Pathogenic
 376300 rs756091827 GRCh37: 8:128750681-128750681
GRCh38: 8:127738435-127738435
44 PTPN11 NM_002834.5(PTPN11):c.1508G>T (p.Gly503Val) SNV Likely Pathogenic
 40560 rs397507546 GRCh37: 12:112926888-112926888
GRCh38: 12:112489084-112489084
45 NFE2L2 NM_006164.5(NFE2L2):c.85G>T (p.Asp29Tyr) SNV Likely Pathogenic
 376462 rs1057519920 GRCh37: 2:178098960-178098960
GRCh38: 2:177234232-177234232
46 BRAF NM_004333.6(BRAF):c.1742A>G (p.Asn581Ser) SNV Likely Pathogenic
 177776 rs121913370 GRCh37: 7:140453193-140453193
GRCh38: 7:140753393-140753393
47 CTNNB1 NM_001904.4(CTNNB1):c.122C>A (p.Thr41Asn) SNV Likely Pathogenic
 376394 rs121913413 GRCh37: 3:41266125-41266125
GRCh38: 3:41224634-41224634
48 HRAS, LRRC56 NM_005343.4(HRAS):c.37G>A (p.Gly13Ser) SNV Likely Pathogenic
 376323 rs104894228 GRCh37: 11:534286-534286
GRCh38: 11:534286-534286
49 PIK3CA NM_006218.4(PIK3CA):c.1034A>T (p.Asn345Ile) SNV Likely Pathogenic
 376488 rs1057519938 GRCh37: 3:178921552-178921552
GRCh38: 3:179203764-179203764
50 MAP2K1 NM_002755.4(MAP2K1):c.157T>A (p.Phe53Ile) SNV Likely Pathogenic
 376447 rs1057519728 GRCh37: 15:66727441-66727441
GRCh38: 15:66435103-66435103

Cosmic variations for Lung Cancer Susceptibility 3:

8 (show top 50) (show all 35823)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88263727 ZRSR2 lung,NS,carcinoma,adenocarcinoma c.937+1G>T p.? 23:15820317-15820317 21
2 COSM95442728 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 21
3 COSM85262562 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 3:50342996-50342996 21
4 COSM85263435 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 21
5 COSM95441934 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.599+122C>T p.? 3:50342996-50342996 21
6 COSM143112283 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 21
7 COSM101592316 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 21
8 COSM101606460 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 21
9 COSM101614868 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 21
10 COSM101585076 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 21
11 COSM101614672 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.94G>A p.G32R 13:19993166-19993166 21
12 COSM143112460 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 21
13 COSM143103178 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 21
14 COSM101592471 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.369G>C p.E123D 13:19993441-19993441 21
15 COSM102040512 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1439C>A p.S480* 16:72798501-72798501 21
16 COSM102032968 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-7406A>C p.? 16:72958371-72958371 21
17 COSM87286137 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3340C>G p.R1114G 16:72889839-72889839 21
18 COSM102043690 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8060C>T p.S2687L 16:72787474-72787474 21
19 COSM102031099 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7886C>A p.A2629D 16:72787648-72787648 21
20 COSM149303773 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3340C>G p.R1114G 16:72889839-72889839 21
21 COSM149318853 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.331G>A p.E111K 16:72959815-72959815 21
22 COSM149318882 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2680G>T p.D894Y 16:72957466-72957466 21
23 COSM149268808 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.256G>T p.A86S 16:72959890-72959890 21
24 COSM102037223 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-7773G>T p.? 16:72958738-72958738 21
25 COSM102042371 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-6501G>T p.? 16:72957466-72957466 21
26 COSM87273791 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2755G>T p.G919C 16:72950930-72950930 21
27 COSM149260552 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10961C>T p.S3654L 16:72787315-72787315 21
28 COSM87284855 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.4834G>C p.E1612Q 16:72797848-72797848 21
29 COSM102022101 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6240C>G p.F2080L 16:72793700-72793700 21
30 COSM87274581 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7769C>G p.S2590C 16:72794913-72794913 21
31 COSM149303017 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2701G>A p.A901T 16:72957445-72957445 21
32 COSM87287980 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2767G>T p.V923L 16:72950918-72950918 21
33 COSM149309579 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2767G>T p.V923L 16:72950918-72950918 21
34 COSM102032971 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.-23-7046G>T p.? 16:72958011-72958011 21
35 COSM102028052 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2928G>C p.Q976H 16:72797012-72797012 21
36 COSM149263533 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1910G>A p.G637E 16:72958236-72958236 21
37 COSM149322707 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10802C>T p.S3601L 16:72787474-72787474 21
38 COSM87279299 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6293C>T p.S2098L 16:72796389-72796389 21
39 COSM149327483 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1582C>T p.Q528* 16:72958564-72958564 21
40 COSM87274095 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.628G>T p.G210C 16:72959518-72959518 21
41 COSM102037726 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.689G>T p.C230F 16:72889748-72889748 21
42 COSM102022617 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.13G>T p.G5C 16:72950930-72950930 21
43 COSM149265687 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8982C>G p.F2994L 16:72793700-72793700 21
44 COSM87281915 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6289T>G p.F2097V 16:72796393-72796393 21
45 COSM149269636 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7769C>G p.S2590C 16:72794913-72794913 21
46 COSM102047871 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3243C>G p.I1081M 16:72796697-72796697 21
47 COSM149263422 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.941G>A p.R314Q 16:72959205-72959205 21
48 COSM102041859 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1021C>T p.P341S 16:72811678-72811678 21
49 COSM87272331 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.941G>A p.R314Q 16:72959205-72959205 21
50 COSM149290601 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10628C>A p.A3543D 16:72787648-72787648 21

Copy number variations for Lung Cancer Susceptibility 3 from CNVD:

6 (show top 50) (show all 580)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13394 1 1 2300000 Gain Lung adenocarcinoma
2 13409 1 1 2300000 Gain Lung adenocarcinoma
3 13970 1 102000000 107000000 Loss Lung adenocarcinoma
4 13986 1 102200000 107200000 Loss Lung adenocarcinoma
5 14528 1 109314358 109386258 Deletion WDR47 Lung adenocarcinoma
6 15384 1 115048600 115061038 Copy number NRAS Lung adenocarcinoma
7 17560 1 143480000 149410000 Amplification ARNT Lung adenocarcinoma
8 18143 1 144218994 144222801 Amplification RBM8A Lung adenocarcinoma
9 18161 1 144227739 144235088 Amplification PEX11B Lung adenocarcinoma
10 18176 1 144287344 144297903 Amplification PIAS3 Lung adenocarcinoma
11 18223 1 144475951 145932379 Amplification GPR89A Lung adenocarcinoma
12 18385 1 145180914 145234067 Amplification CHD1L Lung adenocarcinoma
13 18405 1 145479805 145564639 Amplification BCL9 Lung adenocarcinoma
14 18433 1 145585791 145609258 Amplification ACP6 Lung adenocarcinoma
15 19003 1 148137824 148138969 Amplification BOLA1 Lung adenocarcinoma
16 19039 1 148305965 148384129 Amplification VPS45 Lung adenocarcinoma
17 19152 1 148885329 148936257 Amplification GOLPH3L Lung adenocarcinoma
18 19199 1 149165511 149203837 Amplification SETDB1 Lung adenocarcinoma
19 19207 1 149221122 149234738 Amplification ANXA9 Lung adenocarcinoma
20 19214 1 149247596 149274813 Amplification PRUNE1 Lung adenocarcinoma
21 19280 1 149399337 149404960 Amplification LYSMD1 Lung adenocarcinoma
22 19287 1 149415557 149429264 Amplification VPS72 Lung adenocarcinoma
23 19299 1 149493820 149506578 Amplification PSMD4 Lung adenocarcinoma
24 19341 1 149638664 149641036 Amplification PSMB4 Lung adenocarcinoma
25 19375 1 149998746 150002664 Amplification MRPL9 Lung adenocarcinoma
26 19378 1 150009206 150029634 Amplification TDRKH Lung adenocarcinoma
27 19432 1 150271605 150276135 Amplification S100A11 Lung adenocarcinoma
28 20047 1 152787674 152797744 Amplification UBE2Q1 Lung adenocarcinoma
29 20052 1 152821157 152867061 Amplification ADAR Lung adenocarcinoma
30 20569 1 153196125 153200882 Amplification PYGO2 Lung adenocarcinoma
31 20571 1 153201397 153213464 Amplification SHC1 Lung adenocarcinoma
32 20591 1 153213790 153218346 Amplification CKS1B Lung adenocarcinoma
33 20592 1 153222440 153232211 Amplification FLAD1 Lung adenocarcinoma
34 20617 1 153302836 153308653 Amplification EFNA4 Lung adenocarcinoma
35 20622 1 153317971 153326638 Amplification EFNA3 Lung adenocarcinoma
36 20838 1 154761820 154809020 Amplification IQGAP3 Lung adenocarcinoma
37 20853 1 154828181 154830715 Amplification NAXE Lung adenocarcinoma
38 20863 1 154936029 154941999 Amplification CRABP2 Lung adenocarcinoma
39 20868 1 154959036 154964835 Amplification ISG20L2 Lung adenocarcinoma
40 20872 1 154973717 154977547 Amplification MRPL24 Lung adenocarcinoma
41 20875 1 154978522 155003341 Amplification HDGF Lung adenocarcinoma
42 20983 1 155749790 155788934 Amplification FCRL5 Lung adenocarcinoma
43 21047 1 156490550 156494682 Amplification CD1A Lung adenocarcinoma
44 21335 1 158163454 158182010 Amplification IGSF9 Lung adenocarcinoma
45 21364 1 158264085 158268407 Amplification PIGM Lung adenocarcinoma
46 21422 1 158525000 158579978 Amplification COPA Lung adenocarcinoma
47 21516 1 159308119 159325966 Amplification NECTIN4 Lung adenocarcinoma
48 21522 1 159336969 159354490 Amplification PFDN2 Lung adenocarcinoma
49 21527 1 159354514 159361857 Amplification NIT1 Lung adenocarcinoma
50 21533 1 159390157 159395270 Amplification UFC1 Lung adenocarcinoma
Sources

Expression for Lung Cancer Susceptibility 3

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Lung Cancer Susceptibility 3 patients vs. healthy controls: 35 (show all 45)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 TNNC1 troponin C1, slow skeletal and cardiac type Lung - 5.28 0.000
2 COL11A1 collagen type XI alpha 1 chain Lung + 5.07 0.000
3 MMP1 matrix metallopeptidase 1 Lung + 4.75 0.000
4 AGER advanced glycosylation end-product specific receptor Lung - 4.69 0.000
5 WIF1 WNT inhibitory factor 1 Lung - 4.60 0.000
6 SOSTDC1 sclerostin domain containing 1 Lung - 4.47 0.000
7 FABP4 fatty acid binding protein 4 Lung - 4.32 0.000
8 CDH3 cadherin 3 Lung + 4.31 0.000
9 FOSB FosB proto-oncogene, AP-1 transcription factor subunit Lung - 4.24 0.000
10 TMEM100 transmembrane protein 100 Lung - 4.20 0.000
11 CLEC3B C-type lectin domain family 3 member B Lung - 4.18 0.000
12 FCN3 ficolin 3 Lung - 4.17 0.000
13 MT1M metallothionein 1M Lung - 4.07 0.000
14 SPP1 secreted phosphoprotein 1 Lung + 4.04 0.000
15 SPINK1 serine peptidase inhibitor Kazal type 1 Lung + 3.96 0.000
16 COL10A1 collagen type X alpha 1 chain Lung + 3.79 0.000
17 CLIC5 chloride intracellular channel 5 Lung - 3.65 0.000
18 ADIRF adipogenesis regulatory factor Lung - 3.65 0.000
19 RAMP2 receptor activity modifying protein 2 Lung - 3.62 0.000
20 HIGD1B HIG1 hypoxia inducible domain family member 1B Lung - 3.60 0.000
21 STXBP6 syntaxin binding protein 6 Lung - 3.59 0.000
22 TMPRSS4 transmembrane serine protease 4 Lung + 3.53 0.000
23 EFCC1 EF-hand and coiled-coil domain containing 1 Lung - 3.47 0.000
24 MFAP4 microfibril associated protein 4 Lung - 3.47 0.000
25 ABCC3 ATP binding cassette subfamily C member 3 Lung + 3.47 0.000
26 TOP2A DNA topoisomerase II alpha Lung + 3.41 0.000
27 TCF21 transcription factor 21 Lung - 3.38 0.000
28 CA4 carbonic anhydrase 4 Lung - 3.38 0.000
29 CYP4B1 cytochrome P450 family 4 subfamily B member 1 Lung - 3.33 0.000
30 GPM6A glycoprotein M6A Lung - 3.30 0.000
31 GINS2 GINS complex subunit 2 Lung + 3.29 0.000
32 NEK2 NIMA related kinase 2 Lung + 3.27 0.000
33 TOX3 TOX high mobility group box family member 3 Lung + 3.24 0.000
34 IL1RL1 interleukin 1 receptor like 1 Lung - 3.21 0.000
35 PKNOX2 PBX/knotted 1 homeobox 2 Lung - 3.21 0.000
36 ABCA8 ATP binding cassette subfamily A member 8 Lung - 3.17 0.000
37 SCGB1A1 secretoglobin family 1A member 1 Lung - 3.17 0.000
38 VEGFD vascular endothelial growth factor D Lung - 3.14 0.000
39 CRABP2 cellular retinoic acid binding protein 2 Lung + 3.11 0.000
40 SGCG sarcoglycan gamma Lung - 3.10 0.000
41 ADAMTS8 ADAM metallopeptidase with thrombospondin type 1 motif 8 Lung - 3.08 0.000
42 SFTPD surfactant protein D Lung - 3.07 0.000
43 MARCO macrophage receptor with collagenous structure Lung - 3.07 0.000
44 COL1A1 collagen type I alpha 1 chain Lung + 3.05 0.000
45 NMU neuromedin U Lung + 3.05 0.000
Search GEO for disease gene expression data for Lung Cancer Susceptibility 3.
Sources

Pathways for Lung Cancer Susceptibility 3

About this section


Pathways directly related to Lung Cancer Susceptibility 3:

# Pathway Source
1 Defective pyroptosis Reactome 66

Pathways related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
mTOR Signaling 65
11.64 ERBB2 EGFR BRAF
2
22q11.2 copy number variation syndrome 74
11.55 PRKN EGFR DGCR5
3
MAPK Pathway 70
Show member pathways
 11.41 ERBB2 EGFR BRAF
4
Bladder cancer 74
10.4 ERBB2 EGFR BRAF
5
Relationship between inflammation, COX-2 and EGFR 74
9.96 EGFR BRAF
Sources

GO Terms for Lung Cancer Susceptibility 3

About this section

Cellular components related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane region GO:0098590 8.96 ERBB2 EGFR
2 obsolete spanning component of plasma membrane GO:0044214 8.62 ERBB2 EGFR

Biological processes related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidyl-tyrosine phosphorylation GO:0018108 9.8 ROS1 ERBB2 EGFR BRAF
2 ERBB2-EGFR signaling pathway GO:0038134 9.62 ERBB2 EGFR
3 regulation of ERK1 and ERK2 cascade GO:0070372 9.43 ROS1 ERBB2 EGFR
4 positive regulation of miRNA catabolic process GO:2000627 9.16 KCNQ1OT1 GAS5
5 lncRNA-mediated post-transcriptional gene silencing GO:0000512 8.62 KCNQ1OT1 GAS5

Molecular functions related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.63 ROS1 ERBB2 EGFR
2 protein tyrosine kinase activity GO:0004713 9.5 ROS1 ERBB2 EGFR BRAF
3 miRNA inhibitor activity via base-pairing GO:0140869 8.62 KCNQ1OT1 GAS5
Sources

Sources for Lung Cancer Susceptibility 3

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....